SH2B1

Across TCGA pan-cancer cohorts, SH2B1 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of SH2B1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SH2B1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SH2B1 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and COAD are the cancer types where SH2B1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SH2B1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	II,III,IV	−0.426	<.001	9	view →
LSCC	Male	III,IV	−0.500	<.001	8	view →
COAD	Male	All	−0.369	<.001	8	view →
HNSC	All	IV	−0.345	<.001	8	view →
CCRCC	Male	All	−0.106	.001	6	view →
OV	All	All	−0.546	.004	2	view →
PDAC	All	All	−0.239	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

SH2B1–LUAD

Open the LUAD breakdown →